| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
143,470,000 |
| Market
Cap: |
5.76(B) |
| Last
Volume: |
998,037 |
Avg
Vol: |
995,265 |
| 52
Week Range: |
$35.18 - $53.55 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 292 |
| Guru Rank Value : 4.1 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Ionis Pharmaceuticals is engaged in RNA-targeted therapeuty. Co.'s commercial products are SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA injection for intrathecal use is a survival motor neuron-2 directed antisense medicine indicated for the treatment of spinal muscular atrophy in pediatric and adult patients. TEGSEDI injection is an RNA-targeted medicine indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. WAYLIVRA is an antisense medicine indicated as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
11,298 |
469,764 |
507,366 |
634,895 |
| Total Sell Value |
$477,835 |
$23,553,002 |
$25,162,121 |
$30,224,270 |
| Total People Sold |
4 |
12 |
13 |
13 |
| Total Sell Transactions |
4 |
44 |
52 |
78 |
| End Date |
2024-02-09 |
2023-11-08 |
2023-05-10 |
2022-05-10 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hougen Elizabeth L |
EVP, Finance & CFO |
• – – |
2023-01-18 |
4 |
S |
$39.70 |
$328,721 |
D/D |
(8,280) |
73,435 |
|
-2% |
|
| Swayze Eric |
EVP Research |
• – – |
2023-01-18 |
4 |
S |
$39.74 |
$223,800 |
D/D |
(5,631) |
30,041 |
|
-2% |
|
| Monia Brett P |
Chief Executive Officer |
• • – |
2023-01-18 |
4 |
S |
$39.49 |
$989,947 |
D/D |
(25,066) |
120,863 |
|
-2% |
|
| Baroldi Joseph |
EVP, Chief Business Officer |
• – – |
2023-01-17 |
4 |
OE |
$0.00 |
$0 |
I/I |
904 |
1,226 |
|
- |
|
| Cadoret-Manier Onaiza |
EVP, Chf GL Pdt Str & Oper Ofc |
• – – |
2023-01-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,197 |
22,286 |
|
- |
|
| Schneider Eugene |
EVP, Chf Clinical Develop Ofcr |
• – – |
2023-01-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,046 |
27,078 |
|
- |
|
| Geary Richard S |
EVP, Chief Development Officer |
• – – |
2023-01-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,983 |
78,356 |
|
- |
|
| Bennett C Frank |
EVP, Chief Scientific Officer |
• – – |
2023-01-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,417 |
74,833 |
|
- |
|
| Oneil Patrick R. |
EVP CLO & General Counsel |
• – – |
2023-01-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,871 |
56,515 |
|
- |
|
| Hougen Elizabeth L |
EVP, Finance & CFO |
• – – |
2023-01-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,154 |
81,715 |
|
- |
|
| Swayze Eric |
EVP Research |
• – – |
2023-01-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,780 |
35,672 |
|
- |
|
| Monia Brett P |
Chief Executive Officer |
• • – |
2023-01-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
57,267 |
145,929 |
|
- |
|
| Klein Joseph III |
Director |
– • – |
2023-01-17 |
4 |
AS |
$40.00 |
$80,000 |
D/D |
(2,000) |
16,791 |
|
-2% |
|
| Hayden Michael R |
Director |
– • – |
2022-10-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,777 |
23,109 |
|
- |
|
| Schneider Eugene |
EVP, Chf Clinical Develop Ofcr |
• – – |
2022-10-17 |
4 |
D |
$46.52 |
$6,699 |
D/D |
(144) |
14,032 |
|
- |
|
| Schneider Eugene |
EVP, Chf Clinical Develop Ofcr |
• – – |
2022-10-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
416 |
14,176 |
|
- |
|
| Swayze Eric |
EVP Research |
• – – |
2022-09-08 |
4 |
AS |
$44.55 |
$20,493 |
D/D |
(460) |
19,892 |
|
-8% |
|
| Oneil Patrick R. |
EVP CLO & General Counsel |
• – – |
2022-08-31 |
4 |
A |
$28.97 |
$3,129 |
D/D |
108 |
34,644 |
|
- |
|
| Hougen Elizabeth L |
EVP, Finance & CFO |
• – – |
2022-08-31 |
4 |
A |
$28.97 |
$5,852 |
D/D |
202 |
58,561 |
|
- |
|
| Bennett C Frank |
EVP, Chief Scientific Officer |
• – – |
2022-08-31 |
4 |
A |
$28.97 |
$5,301 |
D/D |
183 |
55,416 |
|
- |
|
| Swayze Eric |
EVP Research |
• – – |
2022-08-05 |
4 |
AS |
$45.20 |
$45 |
D/D |
(1) |
20,352 |
|
-15% |
|
| Parshall B Lynne |
Director |
– • – |
2022-07-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,998 |
85,478 |
|
- |
|
| Wender Joseph H |
Director |
– • – |
2022-07-15 |
4 |
OE |
$0.00 |
$0 |
I/I |
7,998 |
104,969 |
|
- |
|
| Muto Frederick T |
Director |
– • – |
2022-07-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,998 |
59,597 |
|
- |
|
| Herman Joan E |
Director |
– • – |
2022-07-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,110 |
26,665 |
|
- |
|
1983 Records found
|
|
Page 7 of 80 |
|
|
0.77 (1.88%) 
